(SPA, BLRX, SURW) CRWENewswire Stocks In ActionBioLineRx Ltd BLRX - reported that it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C.
